|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||173.43 - 175.97|
|52 Week Range||142.79 - 191.10|
|PE Ratio (TTM)||15.85|
|Earnings Date||Jan 31, 2018 - Feb 5, 2018|
|Forward Dividend & Yield||4.60 (2.62%)|
|1y Target Est||190.55|
Bill Smead, Smead Capital Management, and Barry James, James Advantage Funds, discuss whether value stocks can drive the market to new highs and their value picks.
THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved medicines and investigational immuno-oncology agents from the Company's robust hematology portfolio and pipeline will be presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Dec. 9-12, 2017. The breadth and depth of data to be presented at ASH highlight Amgen's commitment to advancing treatment options for patients with some of the most difficult-to-treat blood cancers and disorders. Notably at ASH, positive overall survival (OS) results from the Phase 3 ASPIRE trial will be detailed for the first time in an oral presentation, which showed the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) significantly extended OS versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.
THOUSAND OAKS, Calif., Dec. 6, 2017 /PRNewswire/ -- Amgen (AMGN) will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m. ET. David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen, together with other members of Amgen's management team and a clinical investigator, will participate to discuss the Company's oncology program, including our BiTE® immunotherapy platform. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Amgen, Inc. a score of 47. Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Roche Holding Ltd Genusssch. and Johnson & ... Read more (Read more...)
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amgen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Amgen and Regeneron will battle in 2018 after the latter unveils cardiovascular data for its cholesterol drug Praluent.
NEW YORK, Dec. 04, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.
PRESS RELEASE : 4 December 2017, 07:00 CET Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests Agreement aims to deliver faster biomarker results to realize more ...
Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday. Amgen has long seen this development as critical to clearing onerous hurdles to patient access and unlocking the value of the drug, Repatha, which has had anemic sales since its August 2015 approval despite its billion-dollar potential. The injected biotech drug was approved on the basis of its ability to dramatically lower bad LDL cholesterol.
Following FDA Priority Review, Repatha is the Only PCSK9 Inhibitor Approved to Reduce Risk of Heart Attack, Stroke and Coronary Revascularization THOUSAND OAKS, Calif. , Dec. 1, 2017 /PRNewswire/ -- Amgen ...
23 analysts were tracking Bristol-Myers Squibb in November 2017. Six of them recommended a “strong buy” rating, while four recommended a “buy.”
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amgen, Inc. Here are 5 ETFs with the largest exposure to AMGN-US. Comparing the performance and risk of Amgen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $1.42 billion.
Ever wonder how your company retirement plan stacks up against the country's best employers? Take a peek at these great retirement plans.
Amgen could have an edge in the preventative migraine space where it competes against Teva, Lilly and Alder, an analyst says.